Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer’s disease

• Published in: Journal of Neural Transmission 2019-03, Vol.126 (3), p.339-348
• Main Authors: Santos, Joana R. F., Bauer, Chris, Schuchhardt, Johannes, Wedekind, Dirk, Waniek, Katharina, Lachmann, Ingolf, Wiltfang, Jens, Vogelgsang, Jonathan
• Format: Article
• Language: English
• Subjects: Medicine; Medicine & Public Health; Neurology; Neurology and Preclinical Neurological Studies - Original Article; Neurosciences; Psychiatry
• ISSN: 0300-9564; 1435-1463
• DOI: 10.1007/s00702-019-01982-5

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques (senile plaques) and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein. This process leads to neuronal degradation and neuronal death. Phosphorylation of tau protein at threonine 231 (p-tau231) has been shown to be characteristic in post-mortem brain tissue of patients with AD and it can be sensitively detected in cerebrospinal fluid (CSF). Therefore, it may serve as a biomarker to support the diagnosis of AD. In this study, we analysed how well p-tau231 could differentiate between patients suffering from dementia either due or not due to AD by a sandwich enzyme immunoassay. CSF p-tau231 was significantly higher in patients with dementia due to AD than in those with dementia due to other causes. In addition, we studied different factors affecting p-tau231 levels in CSF. We found that apolipoprotein E genotype influences p-tau231 CSF levels. Gender and age did not affect p-tau231 levels in CSF. Our findings indicate that p-tau231 levels in CSF can be a valuable marker for the clinical diagnosis of AD.